tradingkey.logo

MannKind Corp

MNKD
5.250USD
-0.170-3.14%
Fechamento 11/11, 16:00ETCotações atrasadas em 15 min
1.61BValor de mercado
55.14P/L TTM

Mais detalhes de MannKind Corp Empresa

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Informações de MannKind Corp

Código da empresaMNKD
Nome da EmpresaMannKind Corp
Data de listagemJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Número de funcionários407
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 28
Endereço1 Casper Street
CidadeDANBURY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal06810
Telefone18186615000
Sitehttps://mannkindcorp.com/
Código da empresaMNKD
Data de listagemJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.

Executivos da empresa MannKind Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Christine Mundkur, J.D.
Ms. Christine Mundkur, J.D.
Independent Director
Independent Director
27.68K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
24.46K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%
Por RegiãoUSD
Nome
Receita
Proporção
United States
76.53M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%

Distribuição de ações

Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.68%
The Vanguard Group, Inc.
5.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.28%
Outro
78.34%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.68%
The Vanguard Group, Inc.
5.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.28%
Outro
78.34%
Tipos de investidores
Investidores
Proporção
Investment Advisor
23.00%
Investment Advisor/Hedge Fund
17.68%
Hedge Fund
10.68%
Research Firm
3.31%
Individual Investor
1.72%
Bank and Trust
0.62%
Pension Fund
0.32%
Venture Capital
0.03%
Insurance Company
0.03%
Outro
42.62%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
473
171.20M
55.75%
-15.78M
2025Q2
477
184.37M
60.10%
+2.23M
2025Q1
482
184.47M
60.73%
+2.52M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
23.58M
7.69%
+2.13M
+9.93%
Jun 30, 2025
The Vanguard Group, Inc.
18.10M
5.9%
+838.68K
+4.86%
Jun 30, 2025
State Street Investment Management (US)
10.75M
3.5%
+1.28M
+13.47%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.62M
2.48%
+831.48K
+12.25%
Jun 30, 2025
Nitorum Capital, L.P.
7.01M
2.29%
-774.19K
-9.94%
Jun 30, 2025
Two Sigma Investments, LP
5.91M
1.93%
-1.19M
-16.80%
Jun 30, 2025
Avoro Capital Advisors LLC
5.85M
1.91%
-2.90M
-33.14%
Jun 30, 2025
Millennium Management LLC
4.48M
1.46%
-1.34M
-23.03%
Jun 30, 2025
Qube Research & Technologies Ltd
4.07M
1.33%
+825.61K
+25.48%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.05M
1.32%
+528.66K
+15.00%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Invesco Biotechnology & Genome ETF
3.53%
ALPS Medical Breakthroughs ETF
1.01%
Invesco NASDAQ Future Gen 200 ETF
0.57%
VictoryShares Small Cap Free Cash Flow ETF
0.43%
Global X Aging Population ETF
0.31%
SPDR S&P Biotech ETF
0.29%
SPDR S&P Kensho New Economies Composite ETF
0.26%
Timothy Plan US Small Cap Core ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção3.53%
ALPS Medical Breakthroughs ETF
Proporção1.01%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.57%
VictoryShares Small Cap Free Cash Flow ETF
Proporção0.43%
Global X Aging Population ETF
Proporção0.31%
SPDR S&P Biotech ETF
Proporção0.29%
SPDR S&P Kensho New Economies Composite ETF
Proporção0.26%
Timothy Plan US Small Cap Core ETF
Proporção0.22%
ProShares Ultra Nasdaq Biotechnology
Proporção0.17%
Invesco Nasdaq Biotechnology ETF
Proporção0.16%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI